No Data
China Resources Pharmaceutical Group to Renew Cooperation Agreements
CHINARES PHARMA (03320.HK) has signed a strategic cooperation agreement with Banks for 2025.
On December 31, Gelonghui reported that CHINARES PHARMA (03320.HK) announced that on December 31, 2024, the company entered into a 2025 strategic cooperation agreement with CHINARES Banks and a 2025 strategic cooperation agreement with CHINARES REITs, effective from January 1, 2025, and ending on December 31, 2027.
CHINARES PHARMA (03320.HK) has received the approval notice for the supplementary application of its Pharmaceutical, Pentazocine Injection.
CHINARES PHARMA (03320.HK) announced that its subsidiary China Resources Double-Crane Pharmaceutical has received the "Notice of Approval for Supplementary Application of Pharmaceutical" for Pentazocine Injection issued by the National Medical Products Administration, which is considered as having passed the consistency evaluation. The company indicated that Pentazocine Injection is suitable for various types of chronic severe pain, such as cancer pain, traumatic pain, and postoperative pain, and can also be used for preoperative or pre-anesthesia medication as an adjunct for surgical anesthesia. According to information from the National Medical Products Administration, there are a total of three manufacturers of Pentazocine Injection that have been approved for market in China, all of which have passed or are deemed to have passed the consistency evaluation.
CHINARES PHARMA (03320.HK) signed a procurement framework agreement for Information Technology Services with CHINARES Digital.
On December 30, Gelonghui reported that CHINARES PHARMA (03320.HK) announced that on December 30, 2024, the company signed a procurement framework agreement for Information Technology Services with China Resources Digital Technology. Accordingly, the group has agreed to procure Information Technology Services from China Resources Digital Technology Group, effective from January 1, 2025, until December 31, 2027.
How is the quality and supply of Pharmaceuticals guaranteed? The National Healthcare Security Administration held a symposium on centralized procurement of Pharmaceuticals.
On December 26, 2024, the National Healthcare Security Administration held a symposium on centralized procurement of Pharmaceuticals, inviting representatives from the National Medical Products Administration, selected Pharmaceutical enterprises, and research Institutions to communicate and exchange views on recent societal concerns regarding quality assurance of centrally procured Pharmaceuticals and innovative development in the Industry, and to listen to opinions and suggestions.
Zhejiang Zhenyuan Share (000705.SZ) plans to sign the "Capital Increase Agreement" with CHINARES PHARMA.
On December 24th, Gelonghui reported that Zhejiang Zhenyuan Share (000705.SZ) announced that it has carried out a capital increase by introducing strategic investors for its wholly-owned subsidiary, Shaoxing Zhenyuan Pharmaceutical Operation Co., Ltd. (referred to as "Zhenyuan Pharmaceuticals"), through a public listing at the Shaoxing Property Exchange. After review by the exchange and confirmation by the company, CHINARES PHARMA was determined to be the qualified investor for the capital increase, and a "Capital Increase Agreement" is planned to be signed with CHINARES PHARMA at a price of 1.439517 yuan per registered capital, with an increase amount of 119.8618235 million yuan.
No Data
